Sarepta Therapeutics Inc Update on Duchenne Muscular Dystrophy Gene Therapy Program Conference Call Transcript
Good morning, ladies and gentlemen, and welcome to the Sarepta Therapeutics microdystrophin gene therapy update conference call. As a reminder, today's program is being recorded.
I'll now turn the call over to Doug Ingram, President and CEO of Sarepta Therapeutics. Please go ahead.
Good morning, and thank you all for joining us for an update on the clinical data from our 4-patient Phase I Microdystrophin Gene Therapy Program. On this call, we may provide forward-looking statements. I would refer you all to our public filings for the risks and precautions associated with our forward-looking statements.
Now before I turn the discussion over to Dr. Louise Rodino-Klapac, let me put this update in context and explain why we are making it. As you all recall, at the World Muscle conference in Mendoza, Argentina in the fall of 2016, we provided an update on our 4-patient Phase I trial for gene therapy. We provided functional and biomarker results as a last date we had for
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |